<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 169 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page168.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=169">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 169 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 169</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=169"><img src="../thumb/169.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>138 / 2020-04                                                        Blood and Haemopoeitic - 8.2

              THE NOAC* YOU AND YOUR PATIENTS CAN RELY ON


                *NOAC = non-vitamin K oral anticoagulant

   a specif.antagon. Theoret. signific. (requir.caref.monit.of prothrombin   Deep vein thrombos.treatm: 1 mg/kg SC 12 hrly. Contin.till a   Contraindications: Clinic.signific.act.bleed., sev.ren.dis (CrCl
   time). Agents that may enhance the anticoag.eff: Allopurin., dana-  therapeut.anticoag.eff.achiev. Usual. 5-10 days treatm. Init.oral an-  &lt;15 ml/min), hepat.dis.with assoc. coagulopathy & clinic.bleed.risk,
   zol, diazoxide, metronidaz., aminoglycos., alcoh., miconaz., triclofos,   ticoag.ther.when appropr.  concom. antiplatelet med.other than aspirin.
   chloral hydr., chloramphen., phenyt., erythromyc., quinid., dextropro-  Prev.of ischaem.complic.of unstable angina or non-Q-  Side effects: Occult/overt bleed.in pres.of assoc. risk fact., anaem.,
   poxyph., Vit.E & glucag. Agents that may dimin. the anti-coag.eff: OC’s   wave MI: 1 mg/kg 12 hrly SC tog.with 100-325 mg aspirin once   haemorrh., contus., naus., thrombocytopen., hypersens., ocul.haem-
   (oestrogens), carbamazep., griseofulv., glucocortic.& cholestyram.  dly x2-8 days.  orrh. incl. conjunctiv.haemorrh., vag.& urethral haemorrh., hypotens.,
   CIPLA WARFARIN, Cipla Medpro [P/S]  Prev.of extracorporeal thrombus.dur. haemodialys: 1 mg/kg.   epistax., haemoptys., GI haemorrh., haematoches., rect.haemorrh.,
                                Reduc.dos.to 0,5 mg/kg in pts.with high risk of haemorrh.for double
                                                              gingiv.bleed., abnorm. LFT, musc.haemorrh., haematur., post proced.
   Warfarin sodium              vascul. access or 0,75 mg/kg for sngl.vascul.access. Introduc. into ar-  haemorrh.incl.haematoma/wound haemorrh/ vessel punct./catheter
   Indications: Prevent.& managem.of DVT & pulm. embol., prevent.  terial line of the circuit at begin.of sess. with eff.suffic.for a 4 hr.sess.,   site haemorrh., wound secret., incis.site haemorrh., opertiv haemorrh.,
   of thromboembol.in atrial fibrillat./ prosthet.heart valves & post MI,   a furth.dos.of 0,5-1 mg/kg if necess.  brain haemhorr., intracran./intraspin. haemorrh., intra-abdom.haem-
   treatm.of trans. ischaem.attacks.  Treatm.of ac.ST-segm.elevat.MI: Single IV bolus of 30 mg plus   orrh., resp.tract haemorrh., haemorrhoid.haemorrh., haematoches.,
   (S4) TABS. 41/8.2/0120. A38/8.2/0422  1 mg/kg SC dos.follow.by 1 mg/ kg SC every 12 hrs. (max.100 mg   mouth haemorrh., retroperiton.haemorrh., applicat. site haemorrh.,
   709906-001: 1 mg, 100, R92,12  for 1 . 2 dos.only, follow.by 1 mg/kg dos.for remain.dos.). Elderly   traumat.haemorrh.
                                  st
   709905-001: 5 mg, 100, R173,63  pts. &gt; 75 yrs: No init.IV bolus. Init. dos. with 0,75 mg/kg SC every   Warnings and special precautions: Condits with incr.risk of
   Dosage: Individ.dos.accord.to PT or INR. Monit lev.bef.commenc.  12 hrs. (max.75 mg for 1  2 dos.only, follow.by 0,75 mg/kg dos.for   haemorrh.eg congenit./acquir. bleed. disords./act.ulcerat.GI dis./
                                          st
   ther., then on 2  & 3  days of treatm., thereaft.on alt.days until maint.  remain. dos.). If admin.in conjunct.with thrombolyt.give Clexane   bact.endocardit., thrombocytopen., platel.disords./haemorrhage.
         nd
           rd
   dos.est. Maint.PT/INR lev.vary accord.to condit.& thromboembol. risk.  betw.15 mins.bef.& 30 mins.aft.start of fibrinolyt. ther. All pts.  stroke hist./uncontr.sev.hypertens., rec.brain/ spin./ ophthalmolog.
   Init.dos.usual.from 10-15 mg/day x3 days. Maint. dos.range from   to rec.aspirin as soon as STEMI diag.& maint.appropr.1xdly.dos.  surg., discont.if sev.haemorrh. occurs.& init.appropr.treatm., con-
   2,5-10 mg/day. Admin.at same time each day.  unless contraindicat. Recomm.durat.of Clexane treatm: 8 days/  sid.recombin. fact. VIIa ther.if surg.haemostas./fresh frozen plasma
   Contraindications: Other coumar.hypersens., bleed.disords.incl.  until.hosp.disch.whichev.comes first.  transfus.not sucessful but no exper.with use of recombin.fact.VIIa,
   haemophil./leukemia, pept.ulc., other bleed.GI disords., bleed.from   Pts.manag.with Percutan.Coron. Intervent (PCI): Last Clexane   no revers.medicat.for Eliquis, discont.in pres.of incr. haemorrh. risk
   resp./genito-urin.tract., sev./large open wounds (incl.surg.), infect.  SC dos. &lt; 8 hrs. bef.balloon inflat.: no additi.dos need.  Last SC   restart.12-24 hrs.aft.risk ceased, not recom. with dialysis/creatin.
   endocardit., pericardit., pericard.effus., imp. liv./ kidn.funct., hyper-  dos.&gt; 8 hs bef.balloon inflati.: Admin.IV bolus of 0,3 mg/kg.  clear.&lt;15 ml per min/sev. hepat.impairm., mild to mod.hepat.im-
   tens., cerebrovasc.bleed., cerebr./ aort.aneurysm., recent/contem-  Contraindications: Hepar./its derivat.incl.other low weight heparin   pairm., not recomm. with concom.azole-antimycot./HIV prot. inhib-
   plat.neuro-/ ophthal.surg., polyarthrit., vit.C defic., maj.reg. block.   hypersens., hepar.assoc. thrombocytopen., act.bleed., benz.alcoh. hy-  its., concom.strong CYP 3A4 & P-gp induc., incr. bleed.risk with an-
   anaesth., lack of co-operat., inadeq.lab. facilit., pregn.(recog.tera-  persens., pts.at risk of haemorrh.incl.pept. ulc./haemorrhag.bld.disor-  tiplatel.meds., concom. platel.aggregat.inhibit./other antithrombot.
   togen.), breastfeed., threaten.abort., safety & effic.not est.in childr.   ds./ thrombocytopen./ cerebrovasc.disords./infect.endocardit.& sev./   meds not recomm.follow.surg., concom.NSAID’s incl. aspirin, risk of
   und.18 yrs., concom.NSAID.   uncontrol.hypertens., safety in pregn., lactat.& childr. not est., safety   epidur./spin.haematoma with neurax. anaesth./spinal punct.which
   Side-effects: Haemorrh.& conseq.haematoma/ anaem./leucopen.&   for treatm.of venous thrombos.& embol.at home not est., safety &   is incr.with post-op indwell.epidur.cathet./concom.meds affect.hae-
   granulocytos., alopec., fev., GI disturbs., inhibit.vit.K synthes., lipid em-  effic.with prosthet.heart valves not est.  mostas., discont.48 hrs.bef.plann.use of indwell.epidur/intrathec.
   boli, hypersens. & skin reacts., purple toe syndr., skin necros., mouth   Side effects: Bleed.in pres.of assoc.risk fact, fatal retroperiton.&   cathet., remov.epidur. cathet.at least 6 hrs.prior to admin., monit.pts.
   & throat sores & white spots, ren. damage, hepatotox.  intra-cran.bleed.report., intraspin. haematoma report.with concurr.  for S&S of neurolog.impairm., eval.risk vs.benef.in anticoagulat./to
   Special precautions: No abrupt.cessat., elderly, vit.K defic., hy-  anticoag.use and spin./epidur.anaesth.result.in long-term/ perm.   be anticoagulat.pts.for thromboprophylax., safety & effic.not eval.in
   perthyroid., indiv.dos.with reg. prothrombin.time determinat., close   paralys., haematoma risk incr.with high dos. regim./postop.epidur.  pts. undergo.hip fract.surg./pts und.18 yrs., lact.intol., not recom.in
   liaison betwn. drs. in pts.undergo.surg./dent.proced., prolong. diet.   in-dwell.catheter /concom. agents aff.haemostas.e.g. NSAID’s &   pregn/lactat.as safety not est., safety & effc.in pts.bel.18 yrs.not est.,
   defic., infect.dis., intestin.flora disturbs., candidias., antibiot.ther.,   traumat.or rep.neuraxial punct., poss.thrombocytopen. with/ with-  discont. 2-3 days bef.elect.surg./invas.proced.& if not poss.weigh up
   diab., vasculit., polycythaem. vera, allerg./anaphylact.disords., incr.   out arter.thrombos.which may be complic.by organ infarct./limb   bleed.risk vs urgency of intervent.
   risk of osteoporot.fract.due to vit.K defic.esp. on long-term treatm.,   ischaem., loc.reacts., cutan./ syst. allerg.reacts., asymptomat.& re-  Interactions: Incr.expos.with strong CYP3A4 & P-gp inhibit., reduc.
   ven.limb gangrene syndr. poss. precipit., good pt.instruct.incl.women   vers.incr.in liv.enz.lev./platelet counts, hepatit., bld.dyscras., GI bleed.,   expos.with strong CYP3A4 & P-gp induc.eg rifampicin/phenytoin/
   contempl. pregn. Prothromb.time poss.incr.by: collag.dis./ carcino-  haematur., haemarthros.  carbamazepine/ phenobarbitone & St Johns Wort., addit.eff.on anti-
   ma/ CHF/diarrh./hepat.disords. /infect. hepatit./jaund./fev.& poor nu-  Special precautions: Fail.ther.& conseq.clot format. & obstruct.re-  FXa active.with enoxaparin, meds.assoc.with ser.bleed.eg unfraction.
   trit.state. Prothromb.time poss.decr.by: diab.mellit./ hyperlipidaem./   port.in pres.of prosthet.heart valv., avoid neuraxial techniq.when pre-  hepar./ hepar.derivat/FXa inhibit.oligosacchar./direct thrombin II inhib-
   hypothyroid./oed.& heredit.resist. to warfar.ther.  op dos. admin., delay placem./remov.of cathet.for 10-12 hrs. aft.DVT   it./ thrombolytic.agents/ GPIIb/IIIa recept.antagon./ dipyridam/ dex-
   Drug interactions: Agents augment.anticoag. eff: Amiodar./  prophylax.admin.and for 24 hrs.in pts. receiv.high dos., admin.subseq.  tran/sulfinpyraz./Vit.K antagon.& other oral anticoags.not recomm.
   anabol.steroids/aspir.& other NSAIDS/ cimetidine/clofibrate/ disul-  dos.2 hrs.aft. cathet. remov., extreme vigil.& monit.for S&S of neu-  See also MDR page 602.
   firam/ phenylbutaz. & other pyrazolones, sulphinpyraz./ sulphonam./  rolog.impairm.reqd.if anticoagulat.in context of epidur/spin.anaesth.  FRAXIPARINE, Aspen Pharmacare [P/S]
   sulphonylurea-type antidiabet.agents/ thyroid hormon. & ac/chron.  giv., if S&S of spin.haemtoma suspect.diagnos.urgent.& init.spin.  Nadroparin calcium
   alcoh.with liv.impairm. Agents reduc. anticoag.eff: Barbitur./ glu-  cord decompress. treatm., do not use low molecul. weight heparins   Indications: DVT prophylax.which may lead to pulm. embol.in pts.
   tethimide/rifampic./Vit.K & chron.alcoh.without liv.impairm. Agents   interchangab., as antibody mediat. heparin-induc.thrombocytopen.  undergoing hip/knee replacem. surg./abdom.surg.when at risk of
                                risk exists. monit.platel.count at init. of ther.& reg.dur.treatm., allow
   poss.enhanc.anticoag.eff: Alcoh./ allopurin./ aminoglycos./chloral   thromboembol. complicat., DVT treatm.
   hydr./ chloramphen./danazol/dextropropoxyph./diazoxide/erythro-  vasc.access sheath used in percutan.coron. revascularisat. proced.to   (S4) INJ, 31/8.2/0577,0578,0579,
                                remain in place x6-8 hrs. aft. SC admin.then admin.next dos.no soon.
   myc./glucagon/metronidaz./miconaz./phenyt./quinidine/triclofos &   than 6-8 hrs.aft.sheath remov.& observ.site for bleed./ haematoma   874981-018: 2850 IU Axa, 10x0,3 ml syr., R419,47
   Vit.E. Agents poss. reduc. anti-coag.eff: Carbamazep./cholesty-  format., no IMI admin., std.clott.tests cannot be done to monit.treatm.,   875007-007: 3800 IU Axa, 10x0,4 ml syr., R559,30
   ram./ glucocortic./griseofulv.& OC’s (oestrog.) Cert.herb. meds.aug-  sev.liv./kidn. insuff., condits.with incr.bleed.potent., in elderly attent.  875015-018: 5700 IU Axa, 10x0,6 ml syr., R838,95
   ment anticoag.eff.           to dos.interv./concom.meds.esp.antiplatel. meds./low body weight   Dosage: Admin SC only. In all cases contin. through risk period &
   CLEXANE, Sanofi-Aventis [P/S]  geriatr.pts.& those predispos. to decr.ren.funct advis., as incr. expos.   until pt.ambulant. The 0,3 ml & 0,4 ml pre-fill.syr.are for unit dosages
                                                              only and the entire contents of syringe should be inj. The 0,6 ml prefill.
   Enoxaparin sodium            with non weight adjust.prophylact.dos.observ.in low weight pts.  graduat.syr.may be used to admin. adjust.dos.
   Indications: Prev.post-op.venous thrombos.& embol. in high &   (women:&lt;45 kg & males: &lt;57 kg) incr. bleed.risk caref.monit.recomm.  DVT prophylax.in abdom.surg: 0,3 ml (2850 IU Axa) 2 hrs. pre-
   mod.risk pts., ven.thrombo-embol.prophylax.in bedrid.pts.due to   Drug interactions: Discont.agents that may aff. haemostas.prior   op & 8 hrs.aft.surg.with subseq.inj.of 0,3 ml (2850 IU Axa) dly x7
   debilitat. medic.illn., treatm.of deep vein thrombos. with/-out pulm.  to ther.unless strict.indicat.  days aft. surg.
   embol., prev.of ischaem.complic.of unstable angina or non-Q-wave   ELIQUIS, Pfizer &  DVT prophylax.in hip/knee replacem.surg: Indiv. dos.accord.
   MI within 24 hrs of onset. comb.with aspirin (100-325)mg., prev.   Apixaban  to bm.admin.init.dos.12 hrs.pre-op and then 12 hrs.aft.end of surg.
   thrombus. format.in extracorp.circulat. dur. haemodialys., treatm.  Indications: Ven.thromboembol.event prevent.in adults who have   Recomm.dos: Days 1-3: 38 IU Axa/kg once dly. Day 4 onwards: 57 IU
   of ac.ST-segm.elevat.MI (STEMI) incl.pts. to be manag.medic./with   undergone elect.hip/knee replacem. surg., stroke/syst.embol.&   Axa/kg once dly. Admin.for at least 10 days.
   subseq.percutan.coronary intervent. (PCI).  death prevent.in pts.with non-valvul.atrial fibrillat.(NVAF) with one   DVT treatm: Admin.2xdly x10 days adjust.dos. accord.to body
   (S4) INJ., X/8.2/42, 31/8.2/0480, 0481, 0482, 32/8.2/0122  or more risk fact.  weight. &lt; 50 kg: 0,4 ml. 50-59 kg: 0,5 ml, 60-69 kg: 0,6 ml. 70-79 kg:
   788767-003: 10x40 mg, prefill.syringe, R914,88  (S4) TABS. 47/8.2/0463, 0464  0,7 ml, 80-89 kg: 0,8 ml, =90 kg: 0,9 ml.
   851140-009: 10x60 mg, prefill.syringe, R1 310,08  724018-001: 2,5 mg, 60, R983,11  Contraindications: Hepar.hypersens., recent sev.thrombocyto-
   851159-001: 10x80 mg, prefill.syringe, R1 564,60  724019-001:5 mg, 60, R983,11  pen., haemorrhag.bld.disords., act./suspect.haemorrh., childr, par-
   851167-004: 10x100 mg, prefill.syringe, R1 760,51  Dosage: Convert.from or to parenteral anticoags. can be done with   tic.haemorrh. risk condits.eg: aneurysm, hypertens., threat. abort.,
   859710-009: 1x300 mg, multidose vial, R476,98  next sched.dos. Discont.warfar/ other vit.K antagon. (VKA) and start   recent childbirth, infect.endocardit., pericardit., vasculit., act.cavitat.
   Dosage:                      ther.when INR is below 2,0. When convert.to warfar./other vit.K   TB, viscer.Ca, any intracran.tumour, dur./aft.eye/brain/spinal cord
   Post-op venous thrombos.& embol.prophylax: Orthopaed.  antagon.ther.cont.Eliquis for 48 hrs.aft.1  warfar./ VKA ther.dos.  surg. or trauma, prior to lumb.punct./reg. anaesthet. block, act.pept.
                                                 st
   surg.(high risk): 40 mg (0,4 ml) dly.SC with 1st inj.12 hrs.pre-op.   VTE prevent.in elect.hip/knee replacem.surg: 2,5 mg orally   ulcerat., large open surf. surgic./traumat.wounds, sev.ren./hepat.im-
   Contin.for 7-10 days aft. surg. / as long as pt.not ambul. Contin.with   2xdly. Init.dos. 12-24 hrs.aft.surg. Recomm.durat.of treatm: Hip   pairm., mechanic. heart valve prosthesis, pregn.& lactat., IM/IV use.
   40 mg dly.x3 wks. in tot.hip replacem. Gen.surg.(mod risk): 20 mg   replacem.surg.32-38 days. Knee replacem.surg: 10-14 days.  Side effects: Bleed., thrombocytopen., gen. allerg. reacts., cutan.
   (0,2 ml) dly.SC with 1st inj.2 hrs.pre-op. Contin.for 7-10 days aft.surg./  Stroke/syst.embol.& death prevent.in NVAF: 5 mg orally   necros., loc.reacts., eosinophil., rebound hyperlipaem., priapism,
   as long as pt.not ambul.     2xdly. In pts.with at least 2 of follow. Characterist.namely ≥80 yrs/  revers. hypoaldosteronism, osteoporos.& spontan/ compress.fac-
   Venous thrombos.prophylax.in medic.pts: 40 mg SC once dly.  body weight≤ 60 kg/ ser. creatin.clear.≥ 1,5 mg/dL admin.2,5 mg   ture risk, alopec.
   Xmin.6 days and cont.till full ambulat. Xmax.14 days.  orally 2xdly.  Special precautions: Diff.low molecul.hepar. cannot be accept.
                        S4 Pradaxa ® . 110 mg. Each capsule contains 110 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 42/8.2/0131. S4 Pradaxa ® . 150 mg. Each capsule contains 150 mg of dabigatran
                        etexilate base (as mesilate salt). Reg. No. 45/8.2/0162. For full prescribing information refer to the professional information approved by the Regulatory Authority.
                        Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100406. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page168.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>&nbsp;&nbsp;&nbsp;<a href="page174.html">174</a>
             </td>
             <td width="35%"><a href="page170.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page170.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
